At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CMND Clearmind Medicine, Inc.
Closed 09-30 16:00:00 EDT
0.8051
-0.0063
-0.77%
盘后0.7300
-0.0751-9.33%
19:59 EDT
High0.8399Low0.8001Vol99.78K
Open0.8145D1 Closing0.8114Amplitude4.91%
Mkt Cap2.71MTradable Cap2.71MTotal Shares3.37M
T/O81.01KT/O Rate2.96%Tradable Shares3.37M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Clearmind Medicine: Effects 1-for-8 Reverse Share Split, Effective October 5, 2026
THOMSON REUTERS  ·  04:36
Clearmind Medicine: Effects 1-for-8 Reverse Share Split, Effective October 5, 2026
Clearmind Medicine to Consolidate Shares 1-for-8 Oct. 5 on NASDAQ
Reuters  ·  04:32
Clearmind Medicine to Consolidate Shares 1-for-8 Oct. 5 on NASDAQ
NeuroThera Labs Expands U.S. Patent Portfolio in Collaboration with Clearmind Medicine
Reuters  ·  09-23
NeuroThera Labs Expands U.S. Patent Portfolio in Collaboration with Clearmind Medicine
Clearmind Medicine Publishes Three US Patent Applications for LSD, Ketamine, Ibogaine Combinations with PEA
Reuters  ·  09-23
Clearmind Medicine Publishes Three US Patent Applications for LSD, Ketamine, Ibogaine Combinations with PEA
Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.
TIPRANKS  ·  09-17
Clearmind Medicine briefs FDA following psychedelic hearing in Washington D.C.
Clearmind Briefs FDA Panel at Washington Psychedelic Drugs Hearing
Reuters  ·  09-17
Clearmind Briefs FDA Panel at Washington Psychedelic Drugs Hearing
Clearmind Enrolls First AUD Patients in CMND-100 Clinical Trial
Reuters  ·  09-11
Clearmind Enrolls First AUD Patients in CMND-100 Clinical Trial
Clearmind Enrolls First Patients with Alcohol Use Disorder in Cmnd-100 Clinical Trial
THOMSON REUTERS  ·  09-11
Clearmind Enrolls First Patients with Alcohol Use Disorder in Cmnd-100 Clinical Trial
Clearmind Net Loss Narrows to USD 907,291 in Q3 FY26; Cash Climbs to USD 12.04 Million at July 31, 2026
Reuters  ·  09-11
Clearmind Net Loss Narrows to USD 907,291 in Q3 FY26; Cash Climbs to USD 12.04 Million at July 31, 2026
Clearmind Medicine Wins Yale IRB Clearance to Recruit Patients for CMND-100 Trial Parts B and C
Reuters  ·  09-08
Clearmind Medicine Wins Yale IRB Clearance to Recruit Patients for CMND-100 Trial Parts B and C
Clearmind Medicine Receives Yale Irb Approval, Enabling Patient Recruitment for Parts B and C of Cmnd-100 Phase I/Ii Trial, Following Positive Safety Results
THOMSON REUTERS  ·  09-08
Clearmind Medicine Receives Yale Irb Approval, Enabling Patient Recruitment for Parts B and C of Cmnd-100 Phase I/Ii Trial, Following Positive Safety Results
Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million
Reuters  ·  09-04
Clearmind Medicine Agrees to Buy 51% of Charging Robotics for $2.5 Million
Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest
THOMSON REUTERS  ·  09-04
Clearmind Medicine - to Extend $1.50 Mln Loan to Charging Robotics at 4% Interest
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
THOMSON REUTERS  ·  09-04
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares
Reuters  ·  09-03
Clearmind Medicine Sets USD 1 Conversion Price for USD 696,079.50 in Notes into Common Shares
Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients
Reuters  ·  09-01
Clearmind Medicine Starts Phase IIa CMND-100 Trial in Alcohol Use Disorder Patients
Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
THOMSON REUTERS  ·  09-01
Clearmind Reaches Key Milestone: Cmnd-100 Phase Iia NOW Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
TIPRANKS  ·  08-24
SciSparc, Clearmind publish U.S. patent application for MDMA-PEA combination
Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment
Reuters  ·  08-24
Clearmind Medicine Says US Publishes MDMA-PEA Patent Application for PTSD Treatment
Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation
THOMSON REUTERS  ·  08-24
Clearmind Advances Mdma-N-Acylethanolamines Ip for the Treatment of Ptsd Amid Rising U.S. Federal Support for Psychedelic Innovation

Introduction

Company Name.
Clearmind Medicine, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company has a collaboration with Clearmind Medicine Inc. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Issue price:
--